奥马珠单抗单药治疗食物过敏。
Omalizumab as monotherapy for food allergy.
机构信息
Allergy Unit - Area of Translational Research in Pediatric Specialities, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
出版信息
Curr Opin Allergy Clin Immunol. 2021 Jun 1;21(3):286-291. doi: 10.1097/ACI.0000000000000744.
PURPOSE OF REVIEW
To familiarize the reader with the most recent insights in the use of Omalizumab (monoclonal anti-immunoglobulin E) monotherapy in the treatment of patients with severe food allergy.
RECENT FINDINGS
The current data from early stage clinical trials show that Omalizumab may be safe and effective by itself in providing desensitization to one or several foods without requiring allergen exposure.
SUMMARY
In the near future, advances in knowledge will guide the adoption and implementation of any new therapy for food allergy and allow the development of a personalized treatment tailored on the specific patient's profile.
目的综述
使读者熟悉奥马珠单抗（单克隆抗免疫球蛋白 E）单药治疗重度食物过敏患者的最新研究进展。
最近的发现
早期临床试验的现有数据表明，奥马珠单抗本身可能是安全有效的，它可以使患者对一种或多种食物脱敏，而无需暴露于过敏原。
总结
在不久的将来，知识的进步将指导食物过敏任何新疗法的采用和实施，并允许根据特定患者的具体情况制定个性化治疗方案。
Zotero 插件